Image Plus Consultants Limited Q3 FY2025 Earnings Call Summary

Image Plus Consultants Limited (IPCL), operating as Apex Radiology, has reported a net profit of J$43.93 million for its financial year ended February 28, 2025 — an 80.4% decline from the previous year’s earnings. Despite the disappointing results, the company emphasized the groundwork laid for long-term growth through strategic investments and operational improvements.

Financial Snapshot
Revenue fell by 9.6% year-over-year to J$1.08 billion, down from J$1.2 billion in FY2023. Gross profit stood at J$712.27 million, with a gross profit margin of 65.9%, consistent with prior years. However, net profit margins fell sharply from 17.7% in FY2024 to 4.1%.

Operating expenses rose to J$524 million, driven largely by salary adjustments to retain skilled radiographic staff, increased electricity and insurance costs, and depreciation charges related to new equipment. Finance costs more than doubled to J$38.67 million, reflecting capital investments in MRI and mammogram modalities.
Earnings per share dropped to J$0.04, compared to J$0.19 the previous year.
“While the year was below expectations, we believe we’ve made critical investments to secure a stronger and more sustainable future,” said Kisha Anderson, CEO of Apex Radiology.

Scan Volume and Modality Mix
Scan volumes totaled 53,458, slightly below the 2023 figure of 54,840 but down 10% from the peak in 2024. A major factor was the downtime of three CT machines in Q2, which led to a significant revenue shortfall. CT scan income alone declined by approximately J$170 million.

However, newer modalities such as MRI and mammography partially offset this shortfall, contributing an additional J$140 million in revenue. The company’s MRI and mammo segments continue to grow, with scan rates steadily climbing toward target levels of 14–20 scans per day.
“This year underscored the importance of diversifying our revenue base,” Anderson noted. “Without the MRI and mammogram modalities, the hit would have been even more severe.”

Cash Flow and Receivables
IPCL faced cash flow tightening due to delayed payments from the Ministry of Health (MOH), which accounts for roughly a third of its revenue. To manage liquidity, the company entered into a receivables financing agreement in Q3.
Anderson clarified that the structure of the agreement was favorable in terms of flexibility and cost. “We prioritized an approach that allowed us to manage payments without burdening suppliers or compromising service delivery,” she said.
Notably, a significant portion of outstanding MOH receivables has been settled post year-end, with commitments in place for full repayment by June 2025.

Strategic Moves and Outlook
Despite the earnings dip, IPCL made meaningful progress on several strategic fronts:
New Nuclear Medicine Unit: A Siemens Symbia Evo SPECT system will be installed at the 129 Pro location in June 2025, enabling advanced oncology and cardiac imaging. The unit is expected to contribute at least J$10 million monthly in revenue, with an attractive 46% net profit margin.

Joint Venture at 33 Lady Musgrave Road: The company signed a development agreement with Ripton Real Estate to construct a new diagnostic center. IPCL will receive over 20,000 square feet of purpose-built space in exchange for its land contribution.

Inorganic Growth Strategy: IPCL has completed due diligence on two acquisition targets and expects to update shareholders at the upcoming AGM. The goal is to accelerate growth while achieving cost synergies.

Referrals and Marketing: With potential declines in public sector referrals, the company is investing in marketing to grow private physician referrals and enhance its brand among patients and practitioners alike.

Operational Improvements: IPCL is also implementing productivity and efficiency initiatives, focused on revenue-per-employee and optimizing case mix.

Shareholder Considerations
Due to lower earnings, IPCL did not declare a dividend for FY2025 — a reversal from prior years. Anderson acknowledged shareholder concerns and emphasized the company’s commitment to returning to dividend payments as soon as possible.
“Think of this as reinvested dividends. The steps we’ve taken will ensure future value,” she said.

Anderson also addressed the company’s underperforming share price, noting that it does not reflect IPCL’s fundamentals or long-term potential. The company is evaluating the implications of the newly raised junior market capital cap of J$750 million, which could provide further opportunities for expansion and acquisition financing.

Conclusion
While FY2025 was a challenging year for IPCL, the company appears well-positioned for recovery. Strategic investments in technology, partnerships, and potential acquisitions, coupled with operational discipline, suggest that the worst may be behind the company. Shareholders are advised to remain patient as IPCL executes its roadmap for long-term value creation.